In a significant development, British pharmaceutical giant AstraZeneca announced on Wednesday the withdrawal of its COVID-19 vaccine Vaxzevria, citing "commercial reasons" and an abundance of updated vaccine alternatives.
A spokesperson for AstraZeneca stated, "As multiple variant COVID-19 vaccines have since been developed, there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied."
Vaxzevria, one of the earliest vaccines produced during the pandemic, has played a crucial role in global vaccination efforts. However, with the emergence of numerous variant-specific vaccines and updated formulations, demand for the original Vaxzevria has waned.
The decision to withdraw Vaxzevria underscores AstraZeneca's commitment to adapt to evolving vaccination needs and prioritize the supply of updated vaccine versions tailored to combat specific variants of the virus.
A spokesperson for AstraZeneca stated, "As multiple variant COVID-19 vaccines have since been developed, there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied."
Vaxzevria, one of the earliest vaccines produced during the pandemic, has played a crucial role in global vaccination efforts. However, with the emergence of numerous variant-specific vaccines and updated formulations, demand for the original Vaxzevria has waned.
The decision to withdraw Vaxzevria underscores AstraZeneca's commitment to adapt to evolving vaccination needs and prioritize the supply of updated vaccine versions tailored to combat specific variants of the virus.
